1. Home
  2. LAMR vs IONS Comparison

LAMR vs IONS Comparison

Compare LAMR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lamar Advertising Company

LAMR

Lamar Advertising Company

HOLD

Current Price

$130.04

Market Cap

13.1B

Sector

Real Estate

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$83.78

Market Cap

13.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAMR
IONS
Founded
1902
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.1B
13.5B
IPO Year
1996
1991

Fundamental Metrics

Financial Performance
Metric
LAMR
IONS
Price
$130.04
$83.78
Analyst Decision
Buy
Strong Buy
Analyst Count
4
22
Target Price
$131.75
$83.64
AVG Volume (30 Days)
423.6K
2.4M
Earning Date
02-20-2026
02-18-2026
Dividend Yield
4.92%
N/A
EPS Growth
N/A
N/A
EPS
4.24
N/A
Revenue
$2,253,062,000.00
$966,957,000.00
Revenue This Year
$4.38
$29.79
Revenue Next Year
$4.59
$0.46
P/E Ratio
$30.92
N/A
Revenue Growth
2.98
20.41
52 Week Low
$99.84
$23.95
52 Week High
$134.63
$86.74

Technical Indicators

Market Signals
Indicator
LAMR
IONS
Relative Strength Index (RSI) 56.67 57.46
Support Level $124.56 $82.55
Resistance Level $130.20 $84.30
Average True Range (ATR) 2.45 2.53
MACD -0.08 0.35
Stochastic Oscillator 60.81 74.32

Price Performance

Historical Comparison
LAMR
IONS

About LAMR Lamar Advertising Company

Lamar Advertising Co is an outdoor advertising companies in the United States and operates as a Real Estate Investment Trust. It rent space for advertising on billboards, buses, shelters, benches, logo plates and in airport terminals and also offer customers a fully integrated service with all aspects of their display requirements from ad copy production to placement and maintenance. It has two operating segments: billboard and Others. Key revenue is generated from Billboard segment.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: